Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Levofloxacin Workflows for Antibacterial and Bone Research
2026-08-24
Levofloxacin supports complementary antibacterial, osteoblast, and chondrocyte workflows by linking bacterial DNA replication inhibition with measurable effects on bone and cartilage biology. This practical guide covers assay setup, exposure design, calcium deposition analysis, resistance-aware interpretation, and troubleshooting for SKU B1959.
-
KU-60019: ATM Kinase Inhibitor Workflow Guide
2026-08-24
Build reproducible KU-60019 experiments for glioma radiosensitization, DNA damage response inhibition, and migration assays. A practical workflow also shows how to test ATM–metabolism combinations inspired by high-grade serous ovarian cancer research without overstating cross-model evidence.
-
Gramine–CUL3–MTDH Axis in TNBC Ferroptosis
2026-08-23
The reference study identifies Gramine as a natural indole alkaloid that suppresses triple-negative breast cancer by engaging a CUL3–MTDH regulatory pathway linked to ferroptosis. Its integrated chemical, biochemical, cellular, and xenograft experiments provide a mechanistic framework for studying ferroptosis and MTDH ubiquitination in cancer biology research.
-
Recombinant Annexin V Maps Cardiomyocyte Death
2026-08-22
The reference study introduced labeled human recombinant Annexin V as an in vivo probe for early phosphatidylserine externalization after myocardial ischemia and reperfusion. By resolving cell-death timing before conventional DNA-fragmentation methods and responding to a cell-death–blocking intervention, the work established a practical framework for testing cardioprotective strategies.
-
Candida krusei Phase-Specific Apoptosis in BMECs
2026-08-22
The reference study shows that the yeast and hypha phases of Candida krusei trigger bovine mammary epithelial-cell apoptosis through different signaling programs. Its phase-resolved co-culture design links yeast-associated injury mainly to mitochondrial signaling and hypha-associated injury to death ligand/receptor signaling, with TLR- and MAPK-related pathways contributing to both responses.
-
Mitochondrial Calcium Signaling Represses Ferroptosis
2026-08-21
The reference study identifies a direct mechanistic link between mitochondrial calcium uptake, GPX4 acetylation, and repression of ferroptotic cell death. By combining mouse genetics, cancer-cell models, mutational analysis, and structural interpretation, it shows how MCU-dependent mitochondrial metabolism sustains GPX4 activity and tumor growth.
-
GW 4869: Exosome Workflow for Osteogenesis
2026-08-20
Use GW 4869 to separate extracellular-vesicle release effects from direct sphingolipid signaling in BMSC and osteogenesis assays. This practical workflow covers donor-cell treatment, Li-Exo comparisons, controls, dosing, and troubleshooting for more defensible exosome biology.
-
Lysosomal Exocytosis in MPS IVA Cartilage
2026-08-20
A 2026 Disease Models & Mechanisms study identifies enhanced lysosomal exocytosis as a disease-associated feature in galns-mutant zebrafish cartilage. Its central contribution is to connect altered lysosome trafficking with reduced cathepsin activity, disrupted TGFβ/BMP signaling, and abnormal glycosaminoglycan distribution rather than attributing skeletal pathology to storage burden alone.
-
Ang II–HIF-1α-HILPDA Axis in NPC Radioresistance
2026-08-19
The reference study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its experiments connect lipid-droplet regulation with radiation response and suggest that combining angiotensin II receptor blockade with ferroptosis induction merits further preclinical investigation.
-
A-1210477: Mapping MCL-1 Apoptotic Dependency
2026-08-19
A-1210477 is an MCL-1 inhibitor for resolving how cancer cells depend on mitochondrial apoptosis. This guide connects binding, BAX/BAK competence, orthogonal assay design, and translational interpretation without overstating in vivo potential.
-
Batimastat (BB-94): From MMPs to Synapses
2026-08-18
A translational framework for using Batimastat (BB-94) to connect matrix metalloproteinase activity with tumor invasion, angiogenesis, and spatially controlled BDNF processing at developing neuromuscular synapses.
-
GLP-1 (9-36) amide for Receptor Studies
2026-08-18
GLP-1 (9-36) amide supports controlled blockade experiments that separate GLP-1 receptor activity from ligand cross-reactivity. This guide translates cAMP assay findings into practical workflows for GPCR signaling, metabolic regulation, and type 2 diabetes research.
-
LC–MS/MS Maps GS-441524 Prodrug Conversion
2026-08-17
A January 2026 Microchemical Journal study established an LC–MS/MS workflow for tracking conversion of the novel GS-441524 prodrug NGP-1 to GS-441524 across gastric fluid, blood, liver microsomes, and a rat liver-injury model. Its findings support a sequential absorption and biotransformation model that can inform oral prodrug design and GS-441524 pharmacokinetics studies.
-
BEND Lipids Improve mRNA and CRISPR Delivery
2026-08-17
The reference study introduces branched endosomal disruptor lipids as an ionizable-lipid design strategy for improving LNP delivery of mRNA and CRISPR-Cas9 ribonucleoproteins. Its comparative experiments connect terminal lipid branching with enhanced endosomal penetration, hepatic gene-editing performance, and T-cell transfection, while also clarifying the limits of transferring results across cargos and cell types.
-
Palonosetron: Evidence for CINV Prevention
2026-08-16
The review by Ruhlmann and Herrstedt examines how palonosetron’s high-affinity, allosteric 5-HT3 receptor binding and prolonged half-life may translate into durable control of chemotherapy-induced nausea and vomiting. Its central practical contribution is a balanced comparison of palonosetron with earlier 5-HT3 antagonists, while emphasizing separate assessment of acute emesis, delayed symptoms, nausea, and combination antiemetic therapy.